Edition:
United Kingdom

Beigene Ltd (BGNE.OQ)

BGNE.OQ on NASDAQ Stock Exchange Global Select Market

169.13USD
18 Apr 2018
Change (% chg)

-- (--)
Prev Close
$169.13
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
121,261
52-wk High
$182.51
52-wk Low
$34.58

Latest Key Developments (Source: Significant Developments)

Beigene Presents Clinical Data On Pamiparib In Chinese Patients With Ovarian Cancers At The American Association For Cancer Research Annual Meeting
Monday, 16 Apr 2018 

April 16 (Reuters) - Beigene Ltd ::BEIGENE PRESENTS CLINICAL DATA ON PAMIPARIB IN CHINESE PATIENTS WITH OVARIAN CANCERS OR TRIPLE-NEGATIVE BREAST CANCER AT THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING.BEIGENE LTD - PAMIPARIB WAS SHOWN TO BE GENERALLY WELL TOLERATED.BEIGENE LTD - LOOK FORWARD TO ADVANCING PAMIPARIB'S DEVELOPMENT IN CHINA AS WELL AS INITIATING A GLOBAL PHASE 3 TRIAL.BEIGENE - IN PATIENTS WITH OVARIAN, BREAST CANCER, PRELIM RESULTS SUPPORT RECOMMENDED PAMIPARIB DOSING REGIMEN, DEMONSTRATED ANTITUMOR ACTIVITY.BEIGENE-SAW NO DOSE-LIMITING TOXICITIES, FOUND PAMIPARIB TO BE GENERALLY WELL TOLERATED AMONG THE PRE-TREATED PATIENTS WITH OVARIAN, BREAST CANCERS.  Full Article

Beigene Announces Proposed Public Offering
Tuesday, 16 Jan 2018 

Jan 16 (Reuters) - Beigene Ltd ::BEIGENE ANNOUNCES PROPOSED PUBLIC OFFERING.BEIGENE LTD - ‍PUBLIC OFFERING OF ITS AMERICAN DEPOSITARY SHARES (ADSS), EACH REPRESENTING 13 OF ITS ORDINARY SHARES, PAR VALUE $0.0001 PER SHARE​.BEIGENE LTD - ‍BEIGENE INTENDS TO OFFER AND SELL $650 MILLION OF ITS ADSS, BEFORE UNDERWRITING DISCOUNTS AND COMMISSIONS AND ESTIMATED OFFERING EXPENSES​.  Full Article

Beigene And Boehringer Ingelheim Announce Commercial Supply Agreement For Tislelizumab
Tuesday, 9 Jan 2018 

Jan 9 (Reuters) - Beigene Ltd ::BEIGENE AND BOEHRINGER INGELHEIM ANNOUNCE COMMERCIAL SUPPLY AGREEMENT FOR ANTI-PD-1 ANTIBODY TISLELIZUMAB.BEIGENE LTD - BOEHRINGER INGELHEIM WILL MANUFACTURE TISLELIZUMAB IN CHINA UNDER AN EXCLUSIVE MULTI-YEAR ARRANGEMENT, WITH CONTRACT EXTENSION POSSIBLE.BEIGENE LTD - CO ALSO OBTAINED CERTAIN PREFERRED RIGHTS FOR FUTURE CAPACITY EXPANSION BY BOEHRINGER INGELHEIM IN CHINA.  Full Article

Beigene And Mirati Therapeutics Announce Exclusive License Agreement For Sitravatinib In The Asia Pacific Region
Monday, 8 Jan 2018 

Jan 8 (Reuters) - Beigene Ltd ::BEIGENE AND MIRATI THERAPEUTICS ANNOUNCE EXCLUSIVE LICENSE AGREEMENT FOR SITRAVATINIB IN THE ASIA PACIFIC REGION.BEIGENE LTD - MIRATI WILL RETAIN EXCLUSIVE RIGHTS FOR DEVELOPMENT, MANUFACTURING AND COMMERCIALIZATION OF SITRAVATINIB FOR REST OF WORLD..BEIGENE LTD - UNDER AGREEMENT MIRATI WILL RECEIVE AN UPFRONT CASH PAYMENT OF $10 MILLION FROM BEIGENE.BEIGENE - MIRATI ELIGIBLE TO RECEIVE UP TO $123 MILLION OF EXTRA PAYMENTS UPON CERTAIN DEVELOPMENT, REGULATORY AND SALES MILESTONES, AMONG OTHERS.BEIGENE - CO, MIRATI THERAPEUTICS ENTERED AGREEMENT FOR DEVELOPMENT, MANUFACTURING, COMMERCIALIZATION OF MIRATI'S SITRAVATINIB IN ASIA.  Full Article

Beigene Ltd qtrly ‍net income attributable to common shareholders per ADS, diluted $2.54​
Monday, 13 Nov 2017 

Nov 13 (Reuters) - Beigene Ltd ::Beigene reports third quarter 2017 financial results.Beigene Ltd - qtrly ‍net income attributable to common shareholders per ads, diluted $2.54​.  Full Article

Beigene receives approval to initiate clinical trials in China
Thursday, 18 Aug 2016 

Beigene Ltd : Beigene receives approval to initiate clinical trials in china with parp inhibitor BGB-290 .Received clinical trial application approval from China Food And Drug Administration (CFDA) to conduct clinical trials in China with BGB-290.  Full Article

Beigene Q2 earnings per share view $-0.68, revenue view $1.4 mln -- Thomson Reuters I/B/E/S
Wednesday, 10 Aug 2016 

Beigene Ltd : Beigene reports second quarter 2016 financial results . Qtrly net loss per ads $0.73 . Revenue for three months ended June 30, 2016 was $0.39 million, compared to $1.38 million for three months ended June 30, 2015 .Q2 earnings per share view $-0.68, revenue view $1.4 million -- Thomson Reuters I/B/E/S.  Full Article

Beigene reports Q1 loss per share $0.97
Wednesday, 11 May 2016 

Beigene Ltd : Qtrly loss per share $0.97 . Revenue for the three months ended march 31, 2016 was $0.68 million, compared to $1.38 million for the three months ended march 31, 2015 .Beigene reports first quarter 2016 financial results.  Full Article

BRIEF-Beigene Presents Clinical Data On Pamiparib In Chinese Patients With Ovarian Cancers At The American Association For Cancer Research Annual Meeting

* BEIGENE PRESENTS CLINICAL DATA ON PAMIPARIB IN CHINESE PATIENTS WITH OVARIAN CANCERS OR TRIPLE-NEGATIVE BREAST CANCER AT THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING